HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-12-08FDA Approved: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Emtricitabine and Tenofovir Disoproxil Fumarate by Teva Pharmaceuticals, likely updating labelin…
-
FDA approval · 2017-11-28FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (Zidovudine) filed by ViiV Healthcare Company.
-
FDA approval · 2017-11-28FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (zidovudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2017-11-28FDA Approved: RETROVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for RETROVIR (Zidovudine) from ViiV Healthcare Company.
-
FDA approval · 2017-11-22FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for ISENTRESS (raltegravir) from Merck Sharp & Dohme LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-11-22FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Isentress (raltegravir) from Merck Sharp & Dohme LLC.
-
FDA approval · 2017-11-22FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved Merck's supplemental application for Isentress (raltegravir) to modify its labeling related to HIV-1 infection.
-
FDA approval · 2017-11-22FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) from Gilead Sci…
-
FDA approval · 2017-11-21FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Tivicay (dolutegravir) submitted by ViiV Healthcare Company.
-
FDA approval · 2017-11-21FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) from ViiV Healthcare, resulting …
-
FDA approval · 2017-11-21FDA Approved: JULUCA — Original Application (ViiV Healthcare Company)
FDA approved JULUCA (dolutegravir and rilpivirine) as an oral fixed-dose combination for HIV-1 infection in adults who are virologically sup…
-
FDA approval · 2017-11-21FDA Approved: ABACAVIR — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA's generic abacavir under an original ANDA for use in HIV-1 infection as part of combination antiretroviral therap…
-
FDA approval · 2017-10-20FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for Reyataz (atazanavir) submitted by E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2017-10-20FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
FDA approved a supplemental application for REYATAZ (atazanavir) submitted by E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2017-10-13FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
The FDA approved AbbVie’s supplemental application for KALETRA (lopinavir/ritonavir), authorizing changes to the product labeling and/or add…
-
FDA approval · 2017-10-06FDA Approved: NEVIRAPINE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an Original Application for NEVIRAPINE (nevirapine) from Macleods Pharmaceuticals Limited, marking approval of a generic antire…
-
FDA approval · 2017-09-29FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for NORVIR (ritonavir) from AbbVie. The supplement updates the product labeling.
-
FDA approval · 2017-09-29FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for NORVIR (ritonavir) submitted by AbbVie.
-
FDA approval · 2017-09-28FDA Approved: DESCOVY — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for DESCOVY (emtricitabine and tenofovir alafenamide) from Gilead Sciences, updating the drug's labe…
-
FDA approval · 2017-09-25FDA Approved: EPIVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for EPIVIR (lamivudine) filed by ViiV Healthcare Company.
-
FDA approval · 2017-09-25FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) from Gilead Sci…
-
FDA approval · 2017-09-15FDA Approved: EDURANT — Supplemental Application (Janssen Products, LP)
The FDA approved a supplemental application for EDURANT (rilpivirine hydrochloride) submitted by Janssen Products, LP.
-
FDA approval · 2017-08-30FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from G…
-
FDA approval · 2017-08-28FDA Approved: TYBOST — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for Tybost (cobicistat) submitted by Gilead Sciences, Inc., indicating an update to the product labe…
-
FDA approval · 2017-08-21FDA Approved: ODEFSEY — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide) submitted by G…